Valuation: NEOVACS

Market Cap 4.09K 4.57K 3.77K 3.41K 6.38K 435K 6.49K 45.01K 17.95K 228K 17.13K 16.77K 721K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -224K -185K -168K -314K -21.37M -319K -2.21M -883K -11.18M -842K -824K -35.42M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
2.32%
Yield 2023 *
-
Yield 2024 -
1 day-0.52%
1 week-3.50%
Current month-51.75%
1 month-54.09%
3 months-87.93%
6 months-95.18%
Current year-99.89%
1 week 0.09
Extreme 0.09
0.11
1 month 0.09
Extreme 0.09
0.22
Current year 0.09
Extreme 0.09
267
1 year 0.09
Extreme 0.09
500
3 years 0.09
Extreme 0.09
32,000,000
5 years 0.09
Extreme 0.09
351,920,000
10 years 0.09
Extreme 0.09
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman - 16/04/1993
Director/Board Member - -
Director/Board Member - 01/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
2/27/21 A Sell

Chief Executive Officer

2,505,144 1.3796%
2/23/21 A Sell

Chief Executive Officer

6,391,053 3.5196%
2/23/21 A Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%-3.50%-99.98%-100.00% 17.2K
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-2.04%-1.64%+25.67%+54.52% 45.99B
-1.07%-3.51%+17.15%+97.66% 42.45B
-0.24%+0.35%+224.63%+926.43% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.62%+2.77%+36.77%+135.91% 39.25B
Weighted average by Cap. -0.37%+3.13%+49.06%+159.83%

Financials

2023 2024
Net sales 533K 596K 492K 445K 833K 56.71M 846K 5.87M 2.34M 29.68M 2.23M 2.19M 94M 434K 484K 400K 362K 677K 46.13M 688K 4.78M 1.91M 24.14M 1.82M 1.78M 76.47M
Net income -8.74M -9.76M -8.07M -7.3M -13.65M -930M -13.87M -96.24M -38.39M -486M -36.63M -35.85M -1.54B -32.91M -36.75M -30.37M -27.48M -51.38M -3.5B -52.21M -362M -145M -1.83B -138M -135M -5.8B
Net Debt -237K -264K -218K -197K -369K -25.14M -375K -2.6M -1.04M -13.16M -991K -970K -41.68M -205K -229K -189K -171K -320K -21.8M -325K -2.26M -901K -11.41M -859K -841K -36.14M
Projected Income Statement - Annual - NEOVACS
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
29/10/26 €0.0965 -0.52% 234,410
28/10/26 €0.0970 +4.98% 205,639
27/10/26 €0.0924 +2.67% 78,557
26/10/26 €0.0900 -6.35% 70,817
23/10/26 €0.0961 -3.90% 27,636
  1. Stock Market
  2. Stocks
  3. ALNEV Stock